Description: |
Objectives:
- To determine the response rate of cabozantinib in patients with progressive urothelial cancer who have received prior cytotoxic chemotherapy
Eligibility:
- Patients in cohort 1 must have a diagnosis of metastatic, progressive urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis, with histological confirmation at the NIH.
- Patients in cohort 2 must have a diagnosis of bone only metastatic, urothelial carcinoma ofthe bladder, urethra, ureter, or renal pelvis, with histological confirmation at the NIH.
- Patients in cohort 3 must have a diagnosis of non-transitional cell carcinoma cancer (including but not limited to squamous cell, neuroendocrine, adenocarcinoma including
urachal and sarcomatoid) of the bladder, urethra, ureter, or renal pelvis with histological
confirmation at the NIH.
- Patients must have been previously treated, as defined by treatment with at least one prior
cytotoxic chemotherapy regimen or agent. Patients may have received any number of prior
cytotoxic agents.
- 18 years of age or older.
|